If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
27 February 2020 US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.
18 June 2020 MicroPort Orthopedics has sued rival Medacta, accusing it of providing surgeons with “knock-off copies and defaced versions” of MicroPort’s patented surgical tools.
18 June 2020 MicroPort Orthopedics has sued rival Medacta, accusing it of providing surgeons with “knock-off copies and defaced versions” of MicroPort’s patented surgical tools.
27 February 2020 US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.
18 June 2020 MicroPort Orthopedics has sued rival Medacta, accusing it of providing surgeons with “knock-off copies and defaced versions” of MicroPort’s patented surgical tools.
27 February 2020 US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.
